Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Enrollment for Phase 2 clinical study of NKTR-102 completed ahead of schedule

Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.

28 Oct 2009

U.S. PTO awards Endocyte patent for vitamin receptor binding anti-cancer agents

Officials at Endocyte Inc., a cancer drug discovery and development company, announced Tuesday (Oct. 27, 2009) that the company has been awarded a patent from the U.S. Patent and Trademark Office covering vitamin receptor binding anti-cancer agents.

28 Oct 2009

ImmunoCellular Therapeutics presents additional data from its ICT-107 Phase I clinical trial

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is focused on the development of novel immune-based cancer therapies, today announced additional data from its Phase I clinical trial evaluating ICT-107, the Company’s dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme (GBM).

27 Oct 2009

ImmunoCellular Therapeutics to present Phase I clinical trial data of ICT-107 vaccine in New Orleans

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, today announced that it will be presenting today, at the Annual Meeting of the Congress of Neurological Surgeons in New Orleans, Louisiana at 3:15pm central time, data from its Phase I clinical trial investigating the role that its ICT-107 vaccine may play in increasing patient survival and inhibiting tumor progression in patients with glioblastoma, the most common and most aggressive type of primary brain tumor.

26 Oct 2009

CAP commends SACGHS stand against human health-related gene patents

The College of American Pathologists today expressed its support for a key government advisory group's recommendation to create an exemption from liability for infringement of gene patent claims when used for patient care purposes.

24 Oct 2009

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals start Phase 3 trial to evaluate Nexavar tablets

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in an international Phase 3 trial to evaluate Nexavar® (sorafenib) tablets for the treatment of patients with radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer.

23 Oct 2009

Early diagnostic for ovarian cancer to be developed

BioProspecting NB Inc. (BPNBI) and the Atlantic Cancer Research Institute (ACRI) have established a formal collaboration to develop an early diagnostic for ovarian cancer based on BPNBI's unique, proprietary cancer management platform.

23 Oct 2009

Curis to outline Hedgehog Pathway Inhibitor at Annual BIO Investor Forum

Curis, Inc. , a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at the 8th Annual BIO Investor Forum at 4:30 p.m. PDT (7:30 p.m. EDT) on October 28, 2009, at the Palace Hotel in San Francisco, California.

21 Oct 2009

Northwest Biotherapeutics announces long-term data from Phase I and Phase I/II clinical trials of DCVax-Brain

Northwest Biotherapeutics, Inc. today announced further long-term follow-up data, for the period from January through September 2009, from its prior Phase I and Phase I/II clinical trials conducted at UCLA with DCVax®-Brain in patients with Glioblastoma multiforme ("GBM"). GBM is the most rapid and lethal type of brain cancer. During the update period, only one of the twenty patients treated with DCVax®-Brain (in addition to standard of care) died, and that patient had survived for nearly 7 years (80.5 months).

21 Oct 2009

Contribution of glycosaminoglycans to skeletal abnormalities in patients with lysosomal storage diseases demonstrated

A group led by Dr. Dieter Br-mme at the University of British Columbia has demonstrated that glycosaminoglycans (GAGs) contribute to skeletal abnormalities in patients with lysosomal storage diseases. Their report can be found in the November 2009 issue of The American Journal of Pathology.

21 Oct 2009

ImmunoCellular Therapeutics files a provisional patent application

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, announced today that it has filed a provisional patent application at US Patent Office seeking protection of intellectual property relating to novel glycosylated epitopes present in lung cancer, pancreatic cancer and colon cancer that are targeted by the Company’s ICT-109 monoclonal antibody product candidate.

20 Oct 2009

Health Discovery Corporation granted additional patents for Recursive Feature Elimination using Support Vector Machines

Health Discovery Corporation is pleased to announce numerous additional issued patents and Notices of Allowance since its last press release describing its intellectual property portfolio. The Company now has a total of 37 issued patents, 4 Notices of Allowance and 30 pending patent applications.

20 Oct 2009

Seguro Surgical obtains global marketing rights to use a novel abdominal surgery device

Seguro Surgical, Inc., a medical device development company specializing in the commercialization of surgical instrumentation, today announced that it has acquired, from The Johns Hopkins University, the global marketing rights to a novel device for use in abdominal surgery.

20 Oct 2009

Highly educated women deal less well with psychological aspects of breast cancer

Well-educated women and those who live alone are emotionally the hardest hit by breast cancer, according to the findings of a new Australian study announced during October's Breast Cancer Awareness Month.

20 Oct 2009

Ruthenium and Osmium compounds show high levels of activity against ovarian cancer

Drugs made using unusual metals could form an effective treatment against colon and ovarian cancer, including cancerous cells that have developed immunity to other drugs, according to research at the University of Warwick and the University of Leeds.

19 Oct 2009

Access Pharmaceuticals' update on its European commercial launch of Mugard

ACCESS PHARMACEUTICALS, INC. today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy.

15 Oct 2009

New UCL cancer research centre launched in UK

A new centre is launched in London today (Wednesday), joining a select group of Cancer Research UK Centres across the UK.

14 Oct 2009

Compugen, Bayer Schering Pharma sign collaboration agreement for tumor research

Compugen Ltd. announced today that they have signed a collaboration agreement with Bayer Schering Pharma AG, Germany covering the further evaluation of a Compugen discovered tumor target and its splice variants.

13 Oct 2009

Sixth annual Medical Student Research Forum highlights latest findings

Members of Qatar's research and medical community recently gathered at Weill Cornell Medical College in Qatar to learn more about research conducted by the college's pre-medical and medical students.

13 Oct 2009

Women with deleterious gene mutation diagnosed with breast cancer earlier than their previous generation

Women with a deleterious gene mutation are diagnosed with breast cancer six years earlier than relatives of the previous generation who also had the disease and/or ovarian cancer, according to new research from The University of Texas M. D. Anderson Cancer Center.

12 Oct 2009

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Enrollment for Phase 2 clinical study of NKTR-102 completed ahead of schedule

U.S. PTO awards Endocyte patent for vitamin receptor binding anti-cancer agents

ImmunoCellular Therapeutics presents additional data from its ICT-107 Phase I clinical trial

ImmunoCellular Therapeutics to present Phase I clinical trial data of ICT-107 vaccine in New Orleans

CAP commends SACGHS stand against human health-related gene patents

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals start Phase 3 trial to evaluate Nexavar tablets

Early diagnostic for ovarian cancer to be developed

Curis to outline Hedgehog Pathway Inhibitor at Annual BIO Investor Forum

Northwest Biotherapeutics announces long-term data from Phase I and Phase I/II clinical trials of DCVax-Brain

Contribution of glycosaminoglycans to skeletal abnormalities in patients with lysosomal storage diseases demonstrated

ImmunoCellular Therapeutics files a provisional patent application

Health Discovery Corporation granted additional patents for Recursive Feature Elimination using Support Vector Machines

Seguro Surgical obtains global marketing rights to use a novel abdominal surgery device

Highly educated women deal less well with psychological aspects of breast cancer

Ruthenium and Osmium compounds show high levels of activity against ovarian cancer

Access Pharmaceuticals' update on its European commercial launch of Mugard

New UCL cancer research centre launched in UK

Compugen, Bayer Schering Pharma sign collaboration agreement for tumor research

Sixth annual Medical Student Research Forum highlights latest findings

Women with deleterious gene mutation diagnosed with breast cancer earlier than their previous generation

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in